TW201242951A - Bicyclic compound - Google Patents

Bicyclic compound Download PDF

Info

Publication number
TW201242951A
TW201242951A TW100143674A TW100143674A TW201242951A TW 201242951 A TW201242951 A TW 201242951A TW 100143674 A TW100143674 A TW 100143674A TW 100143674 A TW100143674 A TW 100143674A TW 201242951 A TW201242951 A TW 201242951A
Authority
TW
Taiwan
Prior art keywords
group
compound
substituted
ring
reaction
Prior art date
Application number
TW100143674A
Other languages
English (en)
Chinese (zh)
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TW201242951A publication Critical patent/TW201242951A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW100143674A 2010-11-30 2011-11-29 Bicyclic compound TW201242951A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2011175330 2011-08-10

Publications (1)

Publication Number Publication Date
TW201242951A true TW201242951A (en) 2012-11-01

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100143674A TW201242951A (en) 2010-11-30 2011-11-29 Bicyclic compound

Country Status (24)

Country Link
US (1) US8729102B2 (enExample)
EP (1) EP2649062B1 (enExample)
JP (1) JP5824517B2 (enExample)
KR (1) KR20140001965A (enExample)
CN (1) CN103347872B (enExample)
AR (1) AR084032A1 (enExample)
AU (1) AU2011337565A1 (enExample)
BR (1) BR112013013417A2 (enExample)
CA (1) CA2819400A1 (enExample)
CL (1) CL2013001520A1 (enExample)
CO (1) CO6751239A2 (enExample)
CR (1) CR20130281A (enExample)
DO (1) DOP2013000118A (enExample)
EA (1) EA201390794A1 (enExample)
EC (1) ECSP13012719A (enExample)
ES (1) ES2536319T3 (enExample)
MA (1) MA34713B1 (enExample)
MX (1) MX2013006113A (enExample)
PE (1) PE20140161A1 (enExample)
PH (1) PH12013501099A1 (enExample)
SG (1) SG190925A1 (enExample)
TW (1) TW201242951A (enExample)
UY (1) UY33756A (enExample)
WO (1) WO2012074126A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34245B1 (fr) 2010-04-27 2013-05-02 Takeda Pharmaceutcal Company Ltd Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
EP2772485A4 (en) 2011-10-24 2015-06-10 Takeda Pharmaceutical BICYCLIC CONNECTION
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
BR112015028173A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
EP2994139B1 (en) * 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
EP2994138A4 (en) 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
CA2928097A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
ES2874089T3 (es) * 2015-09-29 2021-11-04 Oncotherapy Science Inc Compuesto bicíclico y su uso para inhibir SUV39H2
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
SI3371190T1 (sl) 2015-11-06 2022-08-31 Incyte Corporation Heterociklične spojine kot inhibitorji PI3K gama
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
AU7470098A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
WO2004011460A2 (en) * 2002-07-24 2004-02-05 Qlt, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
KR20050062645A (ko) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 신경병증의 예방 또는 치료제
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
CA2605778A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
PE20070338A1 (es) 2005-08-10 2007-04-16 Takeda Pharmaceutical Derivados heterociclicos como agentes terapeuticos para diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP5260507B2 (ja) 2006-10-19 2013-08-14 武田薬品工業株式会社 インドール化合物
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2351743A4 (en) * 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC COMPOUND
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
MA34245B1 (fr) 2010-04-27 2013-05-02 Takeda Pharmaceutcal Company Ltd Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Also Published As

Publication number Publication date
ECSP13012719A (es) 2013-12-31
PH12013501099A1 (en) 2013-07-08
SG190925A1 (en) 2013-07-31
CN103347872B (zh) 2014-12-24
WO2012074126A9 (en) 2013-06-06
CR20130281A (es) 2013-10-07
PE20140161A1 (es) 2014-02-19
CA2819400A1 (en) 2012-06-07
CO6751239A2 (es) 2013-09-16
DOP2013000118A (es) 2013-09-30
EA201390794A1 (ru) 2013-11-29
AR084032A1 (es) 2013-04-17
MA34713B1 (fr) 2013-12-03
MX2013006113A (es) 2013-11-01
KR20140001965A (ko) 2014-01-07
US8729102B2 (en) 2014-05-20
WO2012074126A1 (en) 2012-06-07
ES2536319T3 (es) 2015-05-22
AU2011337565A1 (en) 2013-07-11
JP5824517B2 (ja) 2015-11-25
EP2649062A1 (en) 2013-10-16
CL2013001520A1 (es) 2013-10-18
EP2649062B1 (en) 2015-04-08
BR112013013417A2 (pt) 2019-09-24
JP2013545718A (ja) 2013-12-26
US20120142714A1 (en) 2012-06-07
CN103347872A (zh) 2013-10-09
UY33756A (es) 2012-06-29
AU2011337565A2 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
TW201242951A (en) Bicyclic compound
TWI726968B (zh) Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN111094288B (zh) 具有mgat-2抑制活性的稠合环衍生物
CN106458934B (zh) 喹喔啉化合物及其用途
CN104684915B (zh) 新型双环衍生物
TW201242965A (en) Ring-fused heterocyclic derivative
TW201010977A (en) Amide compound
TWI648276B (zh) 雜環化合物
TW201036958A (en) Pyridazinone compounds
CN103998432A (zh) 双环化合物
TW201302730A (zh) 吡唑化合物
TW201206911A (en) Bicyclic compound
CN110678450A (zh) 作为核受体激动剂的异噁唑衍生物及其用途
TW201625533A (zh) Ｋｃｎｑ ２至５通道活化劑
TW201427968A (zh) 芳香環化合物
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
CN104039766A (zh) 药物化合物
TWI668214B (zh) 具有sstr5拮抗作用之雜環化合物
TW201006813A (en) Novel compounds
CN101541801A (zh) 稠杂环衍生物及其用途
CN105358544A (zh) 杂环化合物
CN104350040B (zh) 芳环化合物
CN105829303B (zh) 作为离子通道调节剂的稠合杂环化合物
WO2024149242A1 (zh) 一种杂环化合物及其在医药上的应用
TWI298999B (en) Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical